边缘显性年龄相关性TDP-43脑病的临床标准

IF 13 1区 医学 Q1 CLINICAL NEUROLOGY Alzheimer's & Dementia Pub Date : 2025-01-14 DOI:10.1002/alz.14202
David A. Wolk, Peter T. Nelson, Liana Apostolova, Konstantinos Arfanakis, Patricia A. Boyle, Cynthia M. Carlsson, Nick Corriveau-Lecavalier, Penny Dacks, Bradford C. Dickerson, Kimiko Domoto-Reilly, Brittany N. Dugger, Rebecca Edelmayer, David W. Fardo, Michel J. Grothe, Timothy J. Hohman, David J. Irwin, Gregory A. Jicha, David T. Jones, Claudia H. Kawas, Edward B. Lee, Karen Lincoln, Gladys E. Maestre, Elizabeth C. Mormino, Chiadi U. Onyike, Ronald C. Petersen, Gil D. Rabinovici, Rosa Rademakers, Rema Raman, Katya Rascovsky, Robert A. Rissman, Emily Rogalski, Philip Scheltens, Reisa A. Sperling, Hyun-Sik Yang, Lei Yu, Henrik Zetterberg, Julie A. Schneider
{"title":"边缘显性年龄相关性TDP-43脑病的临床标准","authors":"David A. Wolk,&nbsp;Peter T. Nelson,&nbsp;Liana Apostolova,&nbsp;Konstantinos Arfanakis,&nbsp;Patricia A. Boyle,&nbsp;Cynthia M. Carlsson,&nbsp;Nick Corriveau-Lecavalier,&nbsp;Penny Dacks,&nbsp;Bradford C. Dickerson,&nbsp;Kimiko Domoto-Reilly,&nbsp;Brittany N. Dugger,&nbsp;Rebecca Edelmayer,&nbsp;David W. Fardo,&nbsp;Michel J. Grothe,&nbsp;Timothy J. Hohman,&nbsp;David J. Irwin,&nbsp;Gregory A. Jicha,&nbsp;David T. Jones,&nbsp;Claudia H. Kawas,&nbsp;Edward B. Lee,&nbsp;Karen Lincoln,&nbsp;Gladys E. Maestre,&nbsp;Elizabeth C. Mormino,&nbsp;Chiadi U. Onyike,&nbsp;Ronald C. Petersen,&nbsp;Gil D. Rabinovici,&nbsp;Rosa Rademakers,&nbsp;Rema Raman,&nbsp;Katya Rascovsky,&nbsp;Robert A. Rissman,&nbsp;Emily Rogalski,&nbsp;Philip Scheltens,&nbsp;Reisa A. Sperling,&nbsp;Hyun-Sik Yang,&nbsp;Lei Yu,&nbsp;Henrik Zetterberg,&nbsp;Julie A. Schneider","doi":"10.1002/alz.14202","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Limbic predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) is highly prevalent in late life and a common co-pathology with Alzheimer's disease neuropathologic change (ADNC). LATE-NC is a slowly progressive, amnestic clinical syndrome. Alternatively, when present with ADNC, LATE-NC is associated with a more rapid course. With the emergence of anti-amyloid therapeutics, discrimination of LATE-NC from ADNC is critical and will lead to greater clinical recognition of amnestic patients without ADNC. Furthermore, co-pathology with LATE-NC may influence outcomes of these therapeutics. Thus there is a need to identify patients during life with likely LATE-NC. We propose criteria for clinical diagnosis of LATE as an initial framework for further validation. In the context of progressive memory loss and substantial hippocampal atrophy, criteria are laid out for probable (amyloid negative) or possible LATE (amyloid biomarkers are unavailable or when amyloid is present, but hippocampal neurodegeneration is out of proportion to expected pure ADNC).</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Limbic-predominant age-related TDP-43 encephalopathy (LATE) is a highly prevalent driver of neuropathologic memory loss in late life.</li>\n \n <li>LATE neuropathologic change (LATE-NC) is a common co-pathology with Alzheimer's disease neuropathologic change (ADNC) and may influence outcomes with emerging disease-modifying medicines.</li>\n \n <li>We provide initial clinical criteria for diagnosing LATE during life either when LATE-NC is the likely primary driver of symptoms or when observed in conjunction with AD.</li>\n \n <li>Definitions of possible and probable LATE are provided.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 1","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14202","citationCount":"0","resultStr":"{\"title\":\"Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy\",\"authors\":\"David A. Wolk,&nbsp;Peter T. Nelson,&nbsp;Liana Apostolova,&nbsp;Konstantinos Arfanakis,&nbsp;Patricia A. Boyle,&nbsp;Cynthia M. Carlsson,&nbsp;Nick Corriveau-Lecavalier,&nbsp;Penny Dacks,&nbsp;Bradford C. Dickerson,&nbsp;Kimiko Domoto-Reilly,&nbsp;Brittany N. Dugger,&nbsp;Rebecca Edelmayer,&nbsp;David W. Fardo,&nbsp;Michel J. Grothe,&nbsp;Timothy J. Hohman,&nbsp;David J. Irwin,&nbsp;Gregory A. Jicha,&nbsp;David T. Jones,&nbsp;Claudia H. Kawas,&nbsp;Edward B. Lee,&nbsp;Karen Lincoln,&nbsp;Gladys E. Maestre,&nbsp;Elizabeth C. Mormino,&nbsp;Chiadi U. Onyike,&nbsp;Ronald C. Petersen,&nbsp;Gil D. Rabinovici,&nbsp;Rosa Rademakers,&nbsp;Rema Raman,&nbsp;Katya Rascovsky,&nbsp;Robert A. Rissman,&nbsp;Emily Rogalski,&nbsp;Philip Scheltens,&nbsp;Reisa A. Sperling,&nbsp;Hyun-Sik Yang,&nbsp;Lei Yu,&nbsp;Henrik Zetterberg,&nbsp;Julie A. Schneider\",\"doi\":\"10.1002/alz.14202\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <p>Limbic predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) is highly prevalent in late life and a common co-pathology with Alzheimer's disease neuropathologic change (ADNC). LATE-NC is a slowly progressive, amnestic clinical syndrome. Alternatively, when present with ADNC, LATE-NC is associated with a more rapid course. With the emergence of anti-amyloid therapeutics, discrimination of LATE-NC from ADNC is critical and will lead to greater clinical recognition of amnestic patients without ADNC. Furthermore, co-pathology with LATE-NC may influence outcomes of these therapeutics. Thus there is a need to identify patients during life with likely LATE-NC. We propose criteria for clinical diagnosis of LATE as an initial framework for further validation. In the context of progressive memory loss and substantial hippocampal atrophy, criteria are laid out for probable (amyloid negative) or possible LATE (amyloid biomarkers are unavailable or when amyloid is present, but hippocampal neurodegeneration is out of proportion to expected pure ADNC).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>Limbic-predominant age-related TDP-43 encephalopathy (LATE) is a highly prevalent driver of neuropathologic memory loss in late life.</li>\\n \\n <li>LATE neuropathologic change (LATE-NC) is a common co-pathology with Alzheimer's disease neuropathologic change (ADNC) and may influence outcomes with emerging disease-modifying medicines.</li>\\n \\n <li>We provide initial clinical criteria for diagnosing LATE during life either when LATE-NC is the likely primary driver of symptoms or when observed in conjunction with AD.</li>\\n \\n <li>Definitions of possible and probable LATE are provided.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"21 1\",\"pages\":\"\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2025-01-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14202\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/alz.14202\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.14202","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

边缘显性年龄相关性TDP-43脑病神经病理改变(late - nc)在晚年非常普遍,是阿尔茨海默病神经病理改变(ADNC)的常见共同病理。晚期nc是一种缓慢进展的遗忘临床综合征。另外,当出现ADNC时,晚期nc与更快速的病程相关。随着抗淀粉样蛋白疗法的出现,区分LATE-NC和ADNC至关重要,这将使临床对无ADNC的遗忘患者有更大的认识。此外,与LATE-NC的共同病理可能影响这些治疗的结果。因此,有必要在生活中识别可能患有晚期nc的患者。我们提出临床诊断LATE的标准作为进一步验证的初步框架。在进行性记忆丧失和海马实质性萎缩的背景下,制定了可能(淀粉样蛋白阴性)或可能的LATE(淀粉样蛋白生物标志物不可用或当淀粉样蛋白存在时,但海马神经退行性变与预期的纯ADNC不成比例)的标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy

Limbic predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) is highly prevalent in late life and a common co-pathology with Alzheimer's disease neuropathologic change (ADNC). LATE-NC is a slowly progressive, amnestic clinical syndrome. Alternatively, when present with ADNC, LATE-NC is associated with a more rapid course. With the emergence of anti-amyloid therapeutics, discrimination of LATE-NC from ADNC is critical and will lead to greater clinical recognition of amnestic patients without ADNC. Furthermore, co-pathology with LATE-NC may influence outcomes of these therapeutics. Thus there is a need to identify patients during life with likely LATE-NC. We propose criteria for clinical diagnosis of LATE as an initial framework for further validation. In the context of progressive memory loss and substantial hippocampal atrophy, criteria are laid out for probable (amyloid negative) or possible LATE (amyloid biomarkers are unavailable or when amyloid is present, but hippocampal neurodegeneration is out of proportion to expected pure ADNC).

Highlights

  • Limbic-predominant age-related TDP-43 encephalopathy (LATE) is a highly prevalent driver of neuropathologic memory loss in late life.
  • LATE neuropathologic change (LATE-NC) is a common co-pathology with Alzheimer's disease neuropathologic change (ADNC) and may influence outcomes with emerging disease-modifying medicines.
  • We provide initial clinical criteria for diagnosing LATE during life either when LATE-NC is the likely primary driver of symptoms or when observed in conjunction with AD.
  • Definitions of possible and probable LATE are provided.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Alzheimer's & Dementia
Alzheimer's & Dementia 医学-临床神经学
CiteScore
14.50
自引率
5.00%
发文量
299
审稿时长
3 months
期刊介绍: Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
期刊最新文献
Response to the letter titled reply to “Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US” Reply to “Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US” Prevalence of idiopathic normal pressure hydrocephalus in older adult population in Shanghai, China: A population-based observational study Influence of alpha-synuclein on glucose metabolism in Alzheimer's disease continuum: Analyses of α-synuclein seed amplification assay and FDG-PET A brain DNA co-methylation network analysis of psychosis in Alzheimer's disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1